Aspire Biopharma Holdings, Inc. Announces Approval Of Reverse Stock Split Ratio

Rhea-AI Summary

Aspire Biopharma (NASDAQ:ASBP) will effect a one-for-thirty (1:30) reverse stock split of its common stock effective May 11, 2026 at 12:01 AM ET, with post-split trading on Nasdaq under the existing symbol ASBP. The action is intended to bring Aspire into compliance with Nasdaq's minimum bid price requirement. The reverse split will reduce outstanding shares from approximately 36,329,490 to approximately 1,210,983. Outstanding options, warrants, restricted stock awards and equity plan share pools will be adjusted proportionally. No fractional shares will be issued; fractional entitlements will be rounded up to the next whole share.

Positive

• Reverse split intended to restore compliance with Nasdaq minimum bid price requirement
• Outstanding equity awards and options will be adjusted proportionally to preserve holder economics
• Post-split shares will trade under the existing ticker ASBP on Nasdaq

Negative

• Shares outstanding reduced from ~36,329,490 to ~1,210,983, materially shrinking float
• Reverse split may reduce share liquidity due to a ~30x consolidation of shares
• Rounding up fractional shares could modestly alter individual holdings after the split

News Market Reaction – ASBP

-16.67% 4.4x vol

38 alerts

-16.67% Session close to close

+31.9% Peak Tracked

-46.1% Trough Tracked

$969,655 Market Cap

4.4x Rel. Volume

In the May 7 session, ASBP declined 16.67%, reflecting a significant negative market reaction. Argus tracked a peak move of +31.9% during that session. Argus tracked a trough of -46.1% from its starting point during tracking. Our momentum scanner triggered 38 alerts that day, indicating elevated trading interest and price volatility. Trading volume was very high at 4.4x the daily average, suggesting heavy selling pressure.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock dropped -16.7% in the session following this news. The decline reflects how prior reverse ...

Analysis

The stock dropped -16.7% in the session following this news. The decline reflects how prior reverse split news affected Aspire, with the January 1-for-40 action followed by a -26.44% move. A new 1-for-30 split again highlights listing and capital pressures against a backdrop of going‑concern warnings and extensive financing tools. Such history suggests investors have often treated structural share consolidations warily, especially when combined with sizeable authorized share capacity and prior equity credit arrangements.

Key Figures

Reverse split ratio: 1-for-30 Effective time: 12:01 AM Eastern Time Par value: $0.0001 per share +5 more

8 metrics

Reverse split ratio 1-for-30 Common stock reverse stock split effective May 11, 2026

Effective time 12:01 AM Eastern Time Reverse split effectiveness on May 11, 2026

Par value $0.0001 per share Par value of common stock unchanged post-split

Shares outstanding pre-split approximately 36,329,490 million Issued and outstanding common stock before reverse split

Shares outstanding post-split approximately 1,210,983 million Issued and outstanding common stock after reverse split

Special meeting date April 10, 2026 Stockholders approved authority for reverse split

Board approval date April 24, 2026 Board approved 1-for-30 reverse split ratio

New CUSIP 738920305 CUSIP for common stock following reverse split

Previous Stock split Reports

1 past event · Latest: Jan 14 (Negative)

Same Type Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Jan 14	Reverse stock split	Negative	-26.4%	Announced 1-for-40 reverse split to support Nasdaq bid-price compliance.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Prior reverse split news on Jan 14, 2026 saw a sharply negative reaction of -26.44%, suggesting reverse split announcements have historically pressured the stock.

Recent Company History

Recent news shows Aspire using capital actions and corporate events to address listing standards and financing needs. A prior 1-for-40 reverse split in Jan 2026 aimed to restore Nasdaq minimum bid compliance and reduced shares from about 158.8M to 4.0M. Today’s 1-for-30 reverse split continues that pattern of using share structure changes to maintain Nasdaq listing status.

Key Terms

reverse stock split, par value, nasdaq capital market, cusip, +1 more

5 terms

reverse stock split financial

"announced that it will effect a one-for-thirty (1:30) reverse stock split"

A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

par value financial

"common stock, par value $0.0001 per share (the "Common Stock")"

Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.

nasdaq capital market regulatory

"before the opening of trading on The Nasdaq Capital Market ("Nasdaq")"

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

cusip financial

"The new CUSIP number for the Common Stock following the reverse split will be 738920305."

A CUSIP is a nine-character alphanumeric code that uniquely identifies a U.S. or Canadian financial security—such as a stock, bond, or fund share—like a Social Security number for an investment. It matters to investors because brokers, exchanges and record-keepers use the CUSIP to match trades, track ownership, settle transactions and pull accurate records, reducing errors and ensuring money and securities go to the right place.

View in glossary

equity incentive plan financial

"The number of shares available to be awarded under any Equity Incentive Plan, will also be"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ESTERO, FL / ACCESS Newswire / May 7, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, today announced that it will effect a one-for-thirty (1:30) reverse stock split (the "reverse split") of its common stock, par value $0.0001 per share (the "Common Stock"), that will become effective on May 11, 2026, at 12:01 AM Eastern Time, before the opening of trading on The Nasdaq Capital Market ("Nasdaq"). Aspire has requested that its Common Stock begin trading on May 11, 2026, on a post-reverse split basis on the Nasdaq under the existing symbol "ASBP".

The reverse split is primarily intended to bring Aspire into compliance with the minimum bid price requirement for maintaining its listing on the Nasdaq. The new CUSIP number for the Common Stock following the reverse split will be 738920305.

At Aspire's special meeting of stockholders on April 10, 2026 (the "Special Meeting"), Aspire's stockholders approved the proposal to authorize Aspire's board of directors (the "Board"), in its sole and absolute discretion, to file a certificate of amendment (the "Amendment") to Aspire's amended and restated certificate of incorporation to effect the reverse split of the Company at a ratio of one-to-thirty (1:30). On April 24, 2026, the Board approved the reverse split at a ratio of one-to-thirty (1:30), and the Amendment has been filed with the Secretary of State of the State of Delaware, which will become effective on May 11, 2026, at 12:01 AM Eastern Time, before the opening of trading on the Nasdaq.

The reverse split will affect all issued and outstanding shares of Common Stock. All outstanding options, restricted stock awards, warrants and other securities entitling their holders to purchase or otherwise receive shares of Common Stock will be adjusted as a result of the reverse split, as required by the terms of each security. The number of shares available to be awarded under any Equity Incentive Plan, will also be appropriately adjusted. Following the reverse split, the par value of the Common Stock will remain unchanged at $0.0001 per share. The reverse split will not change the authorized number of shares of Common Stock or preferred stock. No fractional shares of Common Stock shall be issued as a result of the Reverse Split, and stockholders who otherwise would be entitled to receive fractional shares of New Common Stock shall be entitled to receive the number of shares of New Common Stock rounded up to the next whole number. The reverse split will affect all stockholders uniformly and will not alter any stockholder's percentage interest in Aspire's equity (other than as a result of the rounding of fractional shares, as set forth above).

The reverse split will reduce the number of shares of Common Stock issued and outstanding from approximately 36,329,490 million to approximately 1,210,983 million.

About Aspire Biopharma, Inc.

Aspire Biopharma has developed a patent-pending sublingual delivery technology that can deliver drugs to the body rapidly and precisely. This technology offers the potential to improve effectiveness and reduce side effects by going directly to the bloodstream and avoiding the gastrointestinal tract. Aspire Biopharma's delivery technology can be applied to many different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning both small and large molecule therapeutics, nutraceuticals and supplements.

For more information, please visit www.aspirebiolabs.com

Aspire Biopharma Holdings, Inc.

Contact

PCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.com

Safe Harbor Statement

Certain statements made in this communication are "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of words such as "estimate," "projects," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "would," "should," "future," "propose," "potential," "target," "goal," "objective," "outlook" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the financial position, business strategy and the plans and objectives of management for future operations. These statements are based on various assumptions, whether or not identified in this communication, and on the current expectations of Aspire's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of the parties, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

SOURCE: Aspire Biopharma Holdings, Inc.

View the original press release on ACCESS Newswire

FAQ

What is the reverse stock split for Aspire Biopharma (ASBP) and when is it effective?

It is a one-for-thirty (1:30) reverse split effective May 11, 2026 at 12:01 AM ET. According to the company, the Amendment filed in Delaware becomes effective then and Nasdaq trading will reflect the post-split shares.

How many Aspire (ASBP) shares will be outstanding after the 1:30 reverse split?

Post-split outstanding shares will be approximately 1,210,983. According to the company, this reduces current outstanding shares from about 36,329,490 to the stated post-split total.

Will Aspire (ASBP) change its ticker or CUSIP after the reverse split?

The company will keep the existing ticker ASBP, and the new CUSIP will be 738920305. According to the company, trading resumes May 11, 2026 on a post-split basis under the same symbol.

How will Aspire (ASBP) option, warrant and equity awards be treated in the reverse split?

All outstanding options, warrants, restricted stock awards and equity plan shares will be adjusted proportionally. According to the company, adjustments follow each security's terms to reflect the one-for-thirty ratio.

Will shareholders receive fractional Aspire (ASBP) shares after the reverse split?

No fractional shares will be issued; fractional entitlements will be rounded up to the next whole share. According to the company, rounding up replaces issuing fractional share certificates or cash-in-lieu payments.